Previous 10 | Next 10 |
BioCryst Pharmaceuticals ( NASDAQ: BCRX ) is scheduled to announce Q4 earnings results on Tuesday, February 21st, before market open. The consensus EPS Estimate is -$0.20 (+50.0% Y/Y) and the consensus Revenue Estimate is $74.18M (+57.2% Y/Y). Over the last 1 year, BCRX has ...
RESEARCH TRIANGLE PARK, N.C., Feb. 07, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2022 financial results on Tuesday, February 21, 2023. BioCryst management will host a conference call and we...
Summary BioCryst is a biotechnology company developing treatments for rare diseases, with Orladeyo being its lead product. Orladeyo is a plasma kallikrein inhibitor approved for the treatment of hereditary angioedema (HAE) and works by reducing bradykinin levels. In Q3 2022, total r...
RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts featuring data on oral, once-daily ORLADEYO ® (berotralstat) for the prophylactic treatment of hereditary an...
RESEARCH TRIANGLE PARK, N.C., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the pivotal APeX-P trial evaluating oral, once-daily ORLADEYO ® (berotralstat) in pediatric hereditary angioedema ...
BioCryst Pharmaceuticals ( NASDAQ: BCRX ) is collaborating with Swixx BioPharma to commercialize hereditary angioedema attack (HAE) prevention therapy Orladeyo (berotralstat) in Central and Eastern Europe (CEE). HAE is a disorder characterized by recurrent episodes (att...
RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into a collaboration with Swixx BioPharma AG to commercialize ORLADEYO ® (berotralstat) in Central and Eastern Europe (CEE). ...
BioCryst Pharmaceuticals ( NASDAQ: BCRX ) fell ~11% on Monday after announcing lower-than-expected sales for the company's hereditary angioedema therapy Orladeyo. Citing preliminary, unaudited financials, BioCryst ( BCRX ) said net revenue for Orladeyo reached $70.7M in Q4 202...
—ORLADEYO preliminary 2022 full year net revenue of $251.6 million (+105 percent y-o-y)— —ORLADEYO net revenue expected to be no less than $320 million in 2023— —Company expects ORLADEYO peak sales of $1 billion— RESEARCH...
—Company also expanding its discovery platform in complement-mediated diseases, including potent, selective, oral molecules targeting C2— RESEARCH TRIANGLE PARK, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced ...
News, Short Squeeze, Breakout and More Instantly...
BioCryst Pharmaceuticals Inc. Company Name:
BCRX Stock Symbol:
NASDAQ Market:
BioCryst Pharmaceuticals Inc. Website:
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO ® (berotralstat) for t...
2024-06-27 04:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-07 10:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...